Our elegant electrophysiological approach enables detection of translational ERP endpoints such as N1 and MMN-like responses in standard and oddball paradigm stimuli in response to test compounds, benchmarked against NMDA antagonists, (ketamine, MK-801, PCP). Furthermore, our battery of rodent cognition tests provides the opportunity for assessing whether NCEs have the potential utility for treating a range of cognitive impairments associated with schizophrenia compared to atypical antipsychotics such as clozapine.

We also offer ‘classical models’ of positive symptoms, e.g amphetamine-evoked behaviour, using our advanced LABORAS home cage monitoring system.

Disease relevant models we offer include the following:


headThis list is not exhaustive, we are always developing new areas of discovery within our preclinical field of expertise. If there is something particular that is not listed here please do contact us.